Scholars Central

ArticlePublished 30 Aug 2024

Circulating Tumor DNA Analysis Defining the Genomic Landscape of Paragangliomas and Pheochromocytomas

Authors: Lana Khalil, Ali F. Al Sbihi, Jill Tsai, Leylah M Drusbosky, Hiba I Dada, Bassel El-Rayes, Walid Shaib

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Paragangliomas (PGLs) and Pheochromocytomas (PCCs) are rare cancers. There is not standard of care treatments for these cancers. The genomic landscape of PGLs and PCCs is not reported. The aim of this study is to report the mutational difference and assess the feasibility of Next Generation Sequencing (NGS) testing by Circulating Tumor DNA (ctDNA) from patients with PGLs and PCCs. Methods: Molecular alterations in 46 plasma samples were tested using Guardant360® or Guardant360® CDx ctDNA assays from multiple institutions 2016-2021. Single nucleotide variants and indels in 54-83 genes with copy number amplifications and fusions in selected genes were detected. Results: A total of 46 patients (24 PGLs and 22 PCCs) were included. For the 24 PGLs patients, the median age was 55 (range: 28-78); 14 (58%) were male. Of the 22 PCCs patients, the median age was 56 (range: 28-86); 12 (54.5%) were male. The identified genetic alterations were present in 16 (67%) PGLs and 17 (77%) PCCs patients. The 16 PGLs mutations include: TP53 (44%), followed by ATM (25%), FGFR2 (19%), APC (13%), BRAF (13%), BRCA1 (13%), CCND2 (13%), FGFR3 (13%), IDH2 (13%), KRAS (13%), PDGFRA (13%), RB1 (13%), TERT (13%), ALK (6%), ARID1A (6%), BRCA2 (6%), CCND1 (6%), CDK6 (6%), CDK12 (6%), EGFR (6%), FGFR1 (6%), KIT (6%), MET (6%), NF1 (6%), NRAS (6%), PIK3CA (6%), PTEN (6%) and ROS1 (6%). The 17 PCCs alterations include: TP53 (41%), followed by ATM (35%), NF1 (24%), FGFR1 (18%), APC (13%), EGFR (12%), MET (12%), MYC (12%), NOTCH (12%), PDGFRA (12%), TSC1 (12%), AR (6%), ARID1A (13%), BRAF (6%), BRCA1 (6%), BRCA2 (6%), CCND1(6%), CDK6 (6%), CHEK2 (6%), ERBB2 (6%), EZH2 (6%), FGFR2 (6%), IDH2 (6%), KIT (6%), KRAS (6%), NRAS (6%), NTRK1(6%), NTRK2 (6%) and VHL (6%). Conclusion: Liquid biopsy was feasible to detect alterations in PGLs and PCCs patients. ctDNA is a non-invasive method with the ability to detect alterations that could help personalize the treatment options for patients. We report a high rate of Homologous Recombinant Deficiencies (HRD) among the PGLs/PCCs patients highlighting the need for prospective evaluation on clinical trials.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of the Pancreas.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of the Pancreas
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Lana Khalil”
  • BylineArticles whose byline prints “Ali F. Al Sbihi”
  • BylineArticles whose byline prints “Jill Tsai”
  • BylineArticles whose byline prints “Leylah M Drusbosky”
  • BylineArticles whose byline prints “Hiba I Dada”
  • BylineArticles whose byline prints “Bassel El-Rayes”
  • BylineArticles whose byline prints “Walid Shaib”